Our Impact
The Division of Pediatric Gastroenterology's ongoing mission is to promote health and a healthy society that enables the achievement of every child's full potential. We fulfill this mission by providing the highest standard of care, advanced clinical programs, innovative training of future health care providers, and state-of-the-art clinical and translational research.
We are the:
- Only comprehensive intestinal rehabilitation program in North Texas
- One of the most active pediatric hepatology and liver transplant programs in the nation
- One of the largest pediatric IBD centers in the nation and a founding member of the ImproveCareNow Network, consulting with patients worldwide
- Only pediatric intestinal immunology clinic of its kind in North Texas
- Leaders in endoscopic innovation, research, and training, through our Therapeutic Endoscopy Program, winning the North American Society of Pediatric GI Endoscopy prize four times
- Founding site for the Pediatric ERCP Database Initiative
- Only comprehensive celiac disease program in the Dallas-Fort Worth area
- Home to one of the few ANMS-certified pediatric motility labs in the country, performing the entire range of manometry procedures and other specialized motility studies
- Only bowel management program in North Texas for kids with simple and complex anorectal malformations
- Only multidisciplinary abdominal pain program in the area
- Only aerodigestive disorders management program in the area, with pediatric patients referred from all over the nation
2024 Impact
- By the Numbers
By the Numbers
Faculty
- 37 faculty
Clinical
- 5 clinical sites
- 34,307 outpatient encounters
- 9,642 inpatient encounters
Education
- 4 fellows per year
- Advanced training opportunities for IBD, motility, and advanced endoscopy
Research
- 10 active awards
- $1,347,980 total
funding from grants (FY25) - 16 active clinical trials
- $101,870 revenue from clinical trials (FY25)
- 47 publications
- 2,772 citations
- Honors and Awards
Honors and Awards
- NASPGHAN Shwachman Award
Luis F. Sifuentes-Dominguez, M.D.
- Named Texas Children's Hospital Visiting Young Investigator
- Received UTSW Clinical Excellence Award
- Named as an American Gastroenterology Society FORWARD Scholar for her microbiome research
- Received NASPGHAN Young Faculty Investigator Research Award for her work on optimizing precision probiotics in graft verus host disease
Wenqi Li, Ph.D.
- Mentored by Pranav Shivakumar, Ph.D.
- Won the American Association for Study of Liver Diseases Early Career Investigator Award
- Awarded the 2024 Young Investigator Award/George Ferry Award by NASPGHAN for her work on Precision Phenotyping and Risk Prediction in Biliary Atresia
- Top Conference Presentation Locations
Top Conference Presentation Locations
NASPGHAN Annual Meeting, Hollywood, Florida
Cedars-Sinai International Advanced Endoscopy Symposium, Los Angeles, California
Digestive Disease Week, Washington DC
American Pancreatic Association Annual Meeting, Maui, Hawaii
Liver Connect, San Antonio, Texas
European Society for Pediatric GI, Hepatology and Nutrition, Milan, Italy
American Medical Informatics Association Symposium 2024, San Francisco, California
World Congress of Pediatric GI, Hepatology and Nutrition, Buenos Aires, Argentina
AASLD Annual Meeting, San Diego, California
NACFC 2024, Boston, Massachusetts
- Top Peer-Reviewed Publications and Book Chapters
Top Peer-Reviewed Publications and Book Chapters
Tan S, Santolaya JL, Wright TF, Liu Q, Fujikawa T, Chi S, Bergstrom CP, Lopez A, Chen Q, Vale G, McDonald JG, Schmidt A, Vo N, Kim J, Baniasadi H, Li L, Zhu G, He TC, Zhan X, Obata Y, Jin A, Jia D, Elmquist JK, Sifuentes-Dominguez L, Burstein E. Interaction between the gut microbiota and colonic enteroendocrine cells regulates host metabolism. Nat Metab. 2024 Jun;6(6):1076-1091. doi: 10.1038/s42255-024-01044-5. Epub 2024 May 22.PMID: 38777856
Ramai D, Pan CW, Troendle DM, Maida M, Facciorusso A, Machicado JD; Pancreatology Working Group. Prevalence of Gastroparesis in Chronic Pancreatitis and Predictive Factors: A Machine Learning Prediction Model. Clin Gastroenterol Hepatol. 2024 Oct 26:S1542-3565(24)00961-3. doi: 10.1016/j.cgh.2024.09.023. PMID 39490948
Pandurangi S, Malik A, Owens J, Valencia CA, Miethke AG; Center for Autoimmune Liver Disease Research Group. Deleterious variants in TNFAIP3 are associated with type II and seronegative pediatric autoimmune hepatitis. J Hepatol. 2024 Jan;80(1):e26-e28. PMID: 37821019; PMCID: PMC11303014.
Resnicow K, Delacroix E, Sonneville KR, Considine S, Grundmeier RW, Shu D, Faerber JA, Fiks AG, Steffes J, Harris D, Woo H, Proctor T, Wright ME, Shone LP, Barlow SE, Wasserman RC, Siegel R, Stockwell MS. Outcome of BMI2+: Motivational interviewing to reduce BMI through primary care AAP PROS practices. Pediatr Jan 1, 2024. 1;153(2):e2023062462. PMID 38282541
Miethke AG, Moukarzel A, Porta G, Covarrubias Esquer J, Czubkowski P, Ordonez F, Mosca A, Aqul AA, Squires RH, Sokal E, D'Agostino D, Baumann U, D'Antiga L, Kasi N, Laborde N, Arikan C, Lin CH, Gilmour S, Mittal N, Chiou FK, Horslen SP, Huber WD, Jaecklin T, Nunes T, Lascau A, Longpre L, Mogul DB, Garner W, Vig P, Hupertz VF, Gonzalez-Peralta RP, Ekong U, Hartley J, Laverdure N, Ovchinsky N, Thompson RJ. Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2024 Jul;9(7):620-631. doi: 10.1016/S2468-1253(24)00080-3. Epub 2024 May 6.
Cohen S, Yerushalmy-Feler A, Rojas I, et al. Juvenile polyposis syndrome in children: the impact of SMAD4 and BMPR1A mutations on clinical phenotype and polyp burden. J Pediatr Gastroenterol Nutr. 2024; 79: 161-167. doi:10.1002/jpn3.12257